Zürcher Nachrichten - Higher cost of US cancer care doesn't improve survival rates: study

EUR -
AED 3.834856
AFN 72.981026
ALL 98.491871
AMD 410.574545
ANG 1.873597
AOA 958.441534
ARS 1062.068709
AUD 1.668164
AWG 1.879297
AZN 1.774656
BAM 1.956632
BBD 2.099092
BDT 124.232814
BGN 1.958008
BHD 0.392267
BIF 3073.606664
BMD 1.044054
BND 1.4119
BOB 7.184054
BRL 6.348575
BSD 1.039642
BTN 88.383574
BWP 14.369109
BYN 3.402246
BYR 20463.455505
BZD 2.089788
CAD 1.4984
CDF 2996.434335
CHF 0.932371
CLF 0.037427
CLP 1032.725839
CNY 7.619298
CNH 7.624449
COP 4583.396412
CRC 524.522987
CUC 1.044054
CUP 27.667427
CVE 110.312953
CZK 25.108921
DJF 185.128703
DKK 7.458302
DOP 63.306913
DZD 140.708819
EGP 53.090769
ERN 15.660808
ETB 129.594994
FJD 2.419125
FKP 0.826872
GBP 0.82945
GEL 2.934095
GGP 0.826872
GHS 15.282497
GIP 0.826872
GMD 75.171679
GNF 8981.818386
GTQ 8.010405
GYD 217.502466
HKD 8.11186
HNL 26.390219
HRK 7.4889
HTG 136.00782
HUF 413.977438
IDR 16852.07323
ILS 3.801792
IMP 0.826872
INR 88.729074
IQD 1361.878967
IRR 43941.619435
ISK 145.113457
JEP 0.826872
JMD 162.65915
JOD 0.740338
JPY 163.428363
KES 134.213278
KGS 90.832546
KHR 4177.776073
KMF 486.659583
KPW 939.647883
KRW 1514.838471
KWD 0.321516
KYD 0.866368
KZT 545.98211
LAK 22754.673557
LBP 93096.577585
LKR 305.22976
LRD 188.690217
LSL 19.139837
LTL 3.08282
LVL 0.631537
LYD 5.108172
MAD 10.463148
MDL 19.149141
MGA 4905.085269
MKD 61.561171
MMK 3391.046186
MNT 3547.694854
MOP 8.322738
MRU 41.345577
MUR 49.280896
MVR 16.080872
MWK 1802.251891
MXN 20.95141
MYR 4.682524
MZN 66.718935
NAD 19.139837
NGN 1614.576632
NIO 38.256264
NOK 11.798806
NPR 141.414119
NZD 1.845107
OMR 0.401651
PAB 1.039642
PEN 3.871246
PGK 4.215792
PHP 61.207138
PKR 289.37392
PLN 4.260093
PYG 8106.446244
QAR 3.789911
RON 4.977322
RSD 117.017747
RUB 107.411783
RWF 1449.216096
SAR 3.922094
SBD 8.752883
SCR 14.548185
SDG 628.007273
SEK 11.498155
SGD 1.414228
SHP 0.826872
SLE 23.801848
SLL 21893.290418
SOS 594.152588
SRD 36.678625
STD 21609.806806
SVC 9.096867
SYP 2623.21688
SZL 19.135135
THB 35.777638
TJS 11.373235
TMT 3.664629
TND 3.312708
TOP 2.445276
TRY 36.741769
TTD 7.056
TWD 34.125736
TZS 2521.389855
UAH 43.600836
UGX 3813.621262
USD 1.044054
UYU 46.369713
UZS 13403.698233
VES 53.742914
VND 26555.509733
VUV 123.952164
WST 2.884499
XAF 656.235982
XAG 0.035143
XAU 0.000398
XCD 2.821607
XDR 0.793037
XOF 656.235982
XPF 119.331742
YER 261.404956
ZAR 19.098632
ZMK 9397.736499
ZMW 28.771231
ZWL 336.184914
  • CMSD

    0.0000

    23.56

    0%

  • RBGPF

    59.9600

    59.96

    +100%

  • SCS

    -0.5800

    11.74

    -4.94%

  • RIO

    -0.0900

    58.64

    -0.15%

  • AZN

    0.9100

    65.35

    +1.39%

  • RELX

    -0.3100

    45.47

    -0.68%

  • NGG

    0.8200

    58.5

    +1.4%

  • GSK

    0.1700

    33.6

    +0.51%

  • BTI

    0.1131

    36.24

    +0.31%

  • BCC

    -0.2600

    122.75

    -0.21%

  • CMSC

    0.0200

    23.86

    +0.08%

  • BCE

    0.0500

    23.16

    +0.22%

  • VOD

    0.0100

    8.39

    +0.12%

  • JRI

    0.1100

    12.06

    +0.91%

  • RYCEF

    -0.0100

    7.27

    -0.14%

  • BP

    0.1900

    28.6

    +0.66%

Higher cost of US cancer care doesn't improve survival rates: study
Higher cost of US cancer care doesn't improve survival rates: study / Photo: SAUL LOEB - AFP/File

Higher cost of US cancer care doesn't improve survival rates: study

The United States spends twice as much on cancer care as the average high-income country, but gets only middle-of-the-table survival results, a study said Friday.

Text size:

The results were published in the Journal of the American Health Association (JAMA) Health Forum.

"There is a common perception that the US offers the most advanced cancer care in the world," said lead author Ryan Chow, who is pursuing a medical degree and PhD at Yale University, in a statement.

America is touted for developing advanced new treatments and approving them faster than other countries, and the team were curious about whether this translated into better outcomes.

Out of 22 high-income countries, the United States was found to have by far the highest spending rate: it spends $200 billion per year on cancer care, or roughly $600 per capita, compared to the average of $300 per capita in high-income countries.

But the researchers found this additional spending did not translate into better population-level cancer mortality rates.

"In other words, countries that spend more on cancer care do not necessarily have better cancer outcomes," said Chow.

The US was only slightly better than average, while six countries -- Australia, Finland, Iceland, Japan, South Korea, and Switzerland -- had both better outcomes and lower spending.

Of the countries examined, South Korea and Japan had the lowest cancer mortality rates, while Denmark had the highest, followed by France.

Smoking is the biggest driver of cancer deaths, a factor expected to make cancer outcomes appear more favorable in countries with traditionally low smoking rates such as the US.

After controlling for smoking rates, they found the US was exactly in the middle. Nine countries -- Australia, Finland, Iceland, Japan, Korea, Luxembourg, Norway, Spain, and Switzerland — had lower smoking-adjusted cancer mortality.

There are a constellation of factors behind surging costs in the US, the team wrote.

Cancer drug expenditures account for 37 percent of privately insured US cancer expenditure, and these drugs cost far more in the US than other countries.

Unlike countries with public health systems, US state-run insurance called Medicaid cannot negotiate drug prices.

Additionally, the US Food and Drug Administration (FDA) does not consider pricing when evaluating drug approvals, unlike other countries such as Britain where cost-effectiveness must be factored.

Much of the growth in drug spending has been attributed to newer types of drugs such as monoclonal antibodies, kinase inhibitors, and immune checkpoint inhibitors, even though the evidence in their favor is often marginal.

Finally, medical care is also more aggressive in the US: "Within the last six months of life, US patients with cancer are admitted to the intensive care unit at twice the rate of other countries and are more likely to receive chemotherapy," the team wrote.

Specialty societies advocate for more screening than guidelines suggest, further increasing costs, and low-risk tumors, such as early-stage prostate cancers, are more often subject to intervention despite evidence they would unlikely cause harm if untreated.

"Other countries and systems have much to teach the US if we could be open to change," said co-author Elizabeth Bradley, president of Vassar College.

Y.Keller--NZN